FDA lifts clinical hold on fitusiran
Alnylam and Sanofi Genzyme announced the FDA has lifted the hold on clinical studies with fitusiran, including the Phase 2 open-label extension study and the ATLAS Phase 3 program. The FDA has now approved the protocol amendments and other updated clinical materials for fitusiran studies. December 15, 2017